What is the current stock price of Anixa Biosciences, Inc. (ANIX)?

As of the latest market data, Anixa Biosciences, Inc. (ANIX) is trading at $2.69. The stock has seen a loss of -1.82% today.

Does Anixa Biosciences, Inc. (ANIX) pay a dividend?

Based on current data, Anixa Biosciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Anixa Biosciences, Inc.?

The current market capitalization of Anixa Biosciences, Inc. (ANIX) is approximately unavailable.

ANIX

Anixa Biosciences, Inc.·Healthcare

2.69

1.825%(−0.05)

Market Closed

3.09

14.870%(+0.40)

After Hours

Last Updated: — ET

52W L: $2.4452W H: $5.46

ANIX NEWS

prnewswire.com

1d ago

Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026

Breast cancer vaccine met primary endpoints and generated protocol-defined immuneresponses in 74% of participants in Phase 1 clinical trial Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data in ongoing Phase 1clincal trial SAN JOSE, Calif., April 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Anixa's Chairman and CEO, will participate in the upcoming RedChip Biotech Resurgence: Platforms and Pipelines of Today's Innovators virtual investor conference on April 16, 2026, at 3:30 pm ET.

prnewswire.com

3d ago

Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026

Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in Phase 1 clinical trial Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data in ongoing Phase 1 clincial trial SAN JOSE, Calif., April 7, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Anixa's Chairman and CEO, will participate in the upcoming Water Tower Research (WTR) Insights Conference on April 14, 2026, at 12:30 pm ET.

prnewswire.com

4d ago

Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs

SAN JOSE, Calif., April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was recently featured in an interview on the Smart Money Circle program hosted by Adam Sarhan.

prnewswire.com

Apr 1

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants SAN JOSE, Calif., April 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a development and manufacturing agreement with Cytovance Biologics (www.cytovance.com), a leading full-service contract development and manufacturing organization ("CDMO") specializing in mammalian and microbially expressed biologics, to produce cGMP clinical materials for its planned Phase 2 clinical trial of its breast cancer vaccine.

prnewswire.com

Mar 30

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial status SAN JOSE, Calif., March 30, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 trial, will be presenting at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, being held April 10 – 13, 2026, in San Juan, Puerto Rico.

prnewswire.com

Mar 12

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

SAN JOSE, Calif., March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, is featured on today's Water Tower Research Healthcare Happenings podcast.

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

1983-10-07

Beta

0.58

Websitewww.anixa.com↗